Decrease Post-Transplant Relapse Using Donor-Derived Expanded NK-Cells

In this Phase I/II clinical trial, the authors investigated the safety and efficacy of high doses of mb-IL21 ex vivo expanded donor-derived NK cells to decrease relapse in 25 patients with myeloid malignancies receiving haploidentical stem-cell transplantation.